CC-93538

DRUG6 trials

Sponsors

Celgene

Conditions

Dermatitis, AtopicEczemaEosinophilic EsophagitisEosinophilic GastroenteritisHealthy Volunteers

Phase 1

Japanese Pharmacokinetic Bridging Study for CC-93538

CompletedNCT04096105

CelgeneHealthy Volunteers

Start: 2019-10-14End: 2020-01-30Updated: 2020-08-24

Study to Evaluate the Pharmacokinetic Comparability of CC-93538 From Two Different Drug Concentrations in Healthy Adult Subjects

CompletedNCT04373187

CelgeneHealthy Volunteers

Start: 2020-06-22End: 2021-05-26Updated: 2021-09-28

Phase 2

A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis

CompletedNCT04800315

CelgeneDermatitis, Atopic, Eczema

Start: 2021-05-14End: 2022-11-09Updated: 2024-01-03

Phase 3

A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

CompletedNCT04753697

CelgeneEosinophilic Esophagitis

Start: 2021-02-22End: 2024-08-29Updated: 2025-03-13

Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

CompletedNCT04991935

CelgeneEosinophilic Esophagitis

Start: 2022-08-09End: 2025-08-14Updated: 2026-04-06

A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis

CompletedNCT05214768

CelgeneEosinophilic Gastroenteritis

Start: 2022-03-04End: 2025-08-22Updated: 2026-09-14

Related Papers

Inflammatory and fibrotic biomarkers in patients with atopic dermatitis treated with cendakimab.

2025-11-19

Cendakimab in Adults and Adolescents with Eosinophilic Esophagitis

NEJM Evidence2025-09-233 citations

Design of a phase 3, randomized, double-blind, placebo-controlled, 48-week study to evaluate the efficacy and safety of cendakimab in adult and adolescent patients with eosinophilic esophagitis.

2024-10-092 citations

Cendakimab in Patients With Moderate to Severe Atopic Dermatitis

JAMA Dermatology2024-07-1717 citations